Grants and Contributions:

Back to search

Title:

Transduced t cells for pre-clinical development of novel cd22 car-t’s

Agreement Number:

969531

Agreement Value:

$528,234.00

Agreement Date:

Jan 15, 2021 - Jun 30, 2021

Description:

This project build on the success of the work done over the last two years in establishing clinical grade manufacturing for both lentivirus and cell products, and in executing the first clinical trial using a made-in-Canada CD19 CAR T-cell therapy. The overarching goal of the Project is to build much needed capacity in point-of-care (POC) manufacturing to support the clinical rollout of novel CAR T-cell products and other personalized cell therapy products with the addition of new POC manufacturing and clinical sites. The Conconi Family Immunotherapy Lab (CFIL) at BC Cancer is the first of four sites to be established and expanded. In parallel, and with direct involvement of the NRC, it will be aimed to initiate a minimum of two new, high-content, academically motivated clinical trials to be completed within the next five years for the benefit of cancer patients from across Canada.

Organization:

National Research Council Canada

Expected Results:

In the short term, anticipated outcomes will be strengthened collaborations across industry, academia, and government to support research excellence. In the medium term, anticipated outcomes will be the development of new and potentially disruptive technologies with collaborators. In the long term, find collaborative solutions to public policy challenges and create stronger innovation systems.

Location:

Vancouver, British Columbia, CA V5Z 4E6

Reference Number:

172-2020-2021-Q4-969531

Agreement Type:

Contribution

Report Type:

Grants and Contributions

Recipient Business Number:

863530135

Recipient Type:

Not-for-profit organization or charity

Recipient's Legal Name:

BC Cancer, part of the Provincial Health Services Authority

Federal Riding Name:

Vancouver Granville

Federal Riding Number:

59036

Program:

Collaborative Science, Technology and Innovation Program - Collaborative R&D Initiatives

Program Purpose:

Collaborate on multiparty research and development programs to catalyze transformative, high-risk, high-reward research with the potential for game-changing scientific discoveries and technological breakthroughs in priority areas.

NAICS Code:

541710 - R&D in the physical, engineering and life sciences